iXCells Biotechnologies USA, Inc., a cell technology company specializing in providing cell-based products and drug discovery service solutions to the global academic, biotech, pharmaceutical, and rare disease communities, announced the appointment of Helge Bastian, PhD, as the company’s new Chief Executive Officer.
The company’s co-founder and former CEO, Lynn Zhang, commented, “iXCells has undergone a remarkable transformation over the past few years adding talented scientists and commercial staff, building infrastructure for scalable growth, and expanding our innovative product and service offering while delivering the best possible service to our valued customers worldwide. To help drive our next phase of growth, we’re thrilled to warmly welcome Helge Bastian to our executive team. Helge brings to iXCells a wealth of entrepreneurial and intrapreneurial leadership experience across the life sciences and healthcare space in building businesses for small and large companies with a proven track record of value creation. Helge’s leadership will be pivotal for shaping the ongoing development and execution of iXCells’ growth in the years ahead.”
Also Read : Stem Cell-Derived Brain Organoids on Ax-3 Mission Seek to Improve Modeling for Neurodegenerative Diseases
“I’m impressed with iXCells outstanding scientific and technology expertise and its pragmatic approach to leverage the highly enabling, Nobel Prize winning iPSC reprogramming and genome editing technologies in combination with its deep knowledge of differentiating mammalian stem cells and developing cell-based assays for generating highly predictive human disease models,” said Dr. Bastian. “I’m simply amazed by the team’s focus to provide best in class cell-based products and drug development and discovery service solutions to the market and equally excited with iXCells’ engagement and assistance to stakeholders from the rare disease community to support patients, clinics, and biopharmaceutical companies in their efforts to develop cell-based solutions and therapies to improve patient’s conditions and even save a patient’s life.
I’m grateful for the opportunity to join iXCells at this important stage in the company’s development and looking forward to working with iXCells’ highly talented team to grow and establish the company as a customer and patient-centric leading provider of disease-relevant human cell models and trusted partner for our customers to accelerate the discovery & development of novel and more effective medicines and therapies.”
Dr. Bastian joins iXCells with a plethora of experiences from the life science and healthcare sector where he contributed to building, growing and revitalizing product, custom-product, and services businesses with a variety of portfolios of innovative and highly enabling technologies or new business models in RUO and regulated markets. Dr. Bastian served as a member of several executive leadership teams and held senior leadership positions with global responsibilities in Germany, Switzerland and USA, such as Thermo Fisher Scientific (VP & General Manager of Sample Preparation and Synthetic Biology businesses), Sigma-Aldrich (VP Global Marketing, Business Development and Strategy for Sigma’s innovative Research Biotech division), SGS (Executive VP/divisional CEO Life Science Services) and QIAGEN (VP, Molecular Diagnostics, VP Global Strategic Marketing, and VP PreAnalytiX, a QIAGEN / Becton Dickinson joint venture). In addition, Dr. Bastian led oncology focused Indivumed and M2GEN (now Aster Insights) as Managing Director & Chief Commercial Officer and CEO, respectively.
SOURCE : BusinessWire